NCT07038369 2026-03-17
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Phase 1 Active not recruiting
Atavistik Bio, Inc
K36 Therapeutics, Inc.
Varian, a Siemens Healthineers Company
Blue Earth Therapeutics Ltd